Publication Name	World Journal of Hepatology
Manuscript ID	21421
Country	Italy

Received	2015-07-11 09:28
Peer-Review Started	2015-07-12 18:13
To Make the First Decision	2015-09-08 10:33
Return for Revision	2015-09-16 17:57
Revised	2015-09-30 18:51
Second Decision	2015-11-27 11:56
Accepted by Journal Editor-in-Chief	2015-11-28 00:54
Accepted by Executive Editor-in-Chief	2015-12-02 14:41
Articles in Press	2015-12-02 14:41
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-12-07 09:48
Publish the Manuscript Online	2015-12-10 15:03

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C
Manuscript Source	Invited Manuscript
All Author List	Andrea Martini, Andrea Gallotta, Patrizia Pontisso and Giorgio Fassina
Funding Agency and Grant Number
Corresponding Author	Dr. Giorgio Fassina, Xeptagen S.p.A., VEGA Science Park, Building Auriga, Via delle Industrie 9, 30175 Marghera, Venice, Italy. fassina@xeptagen.com
Key Words	Hepatitis C virus; Treatment; Prognosis; Squamous cell carcinoma antigen-immunoglobulins M; Cirrhosis
Core Tip	A high public health priority need is the development of biomarkers to screen for liver disease progression in hepatitis C virus (HCV)-positive patients. Serological squamous cell carcinoma antigen-immuno-globulins M has shown the ability to identify patients with progressive liver disease and patients at higher risk of hepatocellular carcinoma development. In this review we summarize the main clinical studies performed using this new circulating biomarker for monitoring cirrhosis progression in HCV-positive patients and to evaluate virological response to antiviral treatment.
Publish Date	2015-12-10 15:03
Citation	Martini A, Gallotta A, Pontisso P, Fassina G. Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C. World J Hepatol 2015; 7(29): 2913-2919
URL	http://www.wjgnet.com/1948-5182/full/v7/i29/2913.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i29.2913

Full Article (PDF)	WJH-7-2913.pdf
Full Article (Word)	WJH-7-2913.doc
Manuscript File	21421-Review.doc
Answering Reviewers	21421-Answering reviewers.pdf
Audio Core Tip	21421-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	21421-Conflict-of-interest statement.pdf
Copyright License Agreement	21421-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	21421-Language certificate.pdf
Peer-review Report	21421-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	21421-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	21421-Scientific misconduct check.pdf
Scientific Editor Work List	21421-Scientific editor work list.pdf